Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May 16;23(1):20.
doi: 10.1186/s12991-024-00505-1.

Individualized strategies for depression: narrative review of clinical profiles responsive to vortioxetine

Affiliations
Review

Individualized strategies for depression: narrative review of clinical profiles responsive to vortioxetine

Alessandro Cuomo et al. Ann Gen Psychiatry. .

Abstract

Background: Depression is a highly heterogeneous disorder, often resulting in suboptimal response and remission rates. This underscores the need for more nuanced clinical characterization of patients to tailor individualized treatment plans. Emerging evidence highlights the critical role of cognitive and emotional dysfunction in major depression, prompting the exploration of novel therapeutic interventions that target these specific symptom domains.

Main text: Vortioxetine, a multimodal antidepressant, enhances serotonergic activity while also modulating several other neurotransmitter systems involved in depressive symptoms such as emotional blunting, anhedonia, and cognitive dysfunction. Numerous randomized, placebo-controlled trials have demonstrated vortioxetine's efficacy and safety in treating depression, particularly in specific subgroups of depressed patients, including those with cognitive deficits and comorbid anxiety symptoms or disorders. Although not randomized or placebo-controlled, studies have also shown vortioxetine's efficacy in depressed patients with emotional blunting or anhedonia. Vortioxetine's ability to effectively treat a range of depressive symptoms, including anhedonia, emotional blunting, anxiety, and cognitive dysfunction, provides an individualized treatment solution for depressed individuals suffering from these symptoms. The purpose of this paper is to identify clinical profiles of patients who may benefit from vortioxetine, with the goal of optimizing therapeutic outcomes.

Conclusion: Vortioxetine has been shown to be effective for patients with depression and symptoms such as anhedonia, emotional blunting, anxiety, and cognitive dysfunction. Tailoring treatment plans to individual needs and personalizing treatment choices based on the specific symptoms presented by depressed patients improve treatment outcomes.

Keywords: Anhedonia; Cognitive dysfunction; Comorbid anxiety symptoms; Depression; Emotional blunting; Individualized treatment; Multimodal Antidepressant; Vortioxetine.

PubMed Disclaimer

Conflict of interest statement

Andrea Fagiolini is /has been a consultant and/or a speaker and/or has received research grants from Angelini, Apsen, Biogen, Boheringer Ingelheim, Idorsia Italfarmaco, Lundbeck, Janssen, Medicamenta, Mylan, Otsuka, Pfizer, Recordati, Sunovion, ViatrisAlessandro Cuomo is /has been a consultant and/or a speaker and/or has received research grants from Angelini, Boheringer Ingelheim, Idorsia Italfarmaco, Lundbeck, Janssen, Medicamenta, Mylan, Otsuka, Pfizer, Recordati, Sunovion, ViatrisNo other authors have conflicts of interest to declare. Alessandro Cuomo is /has been a consultant and/or a speaker and/or has received research grants from Angelini, Boheringer Ingelheim, Idorsia Italfarmaco, Lundbeck, Janssen, Medicamenta, Mylan, Otsuka, Pfizer, Recordati, Sunovion, Viatris. No other authors have conflicts of interest to declare.

References

    1. Uher R. The implications of gene-environment interactions in depression: will cause inform cure? Mol Psychiatry. 2008;13(12):1070–8. - PubMed
    1. Kendler KS, Gardner CO. A longitudinal etiologic model for symptoms of anxiety and depression in women. Psychol Med. 2011;41(10):2035–45. - PMC - PubMed
    1. Arnaez JM, Krendl AC, McCormick BP, Chen Z, Chomistek AK. The association of depression stigma with barriers to seeking mental health care: a cross-sectional analysis. J Ment Health Abingdon Engl. 2020;29(2):182–90. - PubMed
    1. van Eeden WA, van Hemert AM, Carlier IVE, Penninx BW, Giltay EJ. Severity, course trajectory, and within-person variability of individual symptoms in patients with major depressive disorder. Acta Psychiatr Scand. 2019;139(2):194–205. - PMC - PubMed
    1. Arnaud AM, Brister TS, Duckworth K, Foxworth P, Fulwider T, Suthoff ED, et al. Impact of treating Depression on Associated comorbidities: a systematic literature review. Prim Care Companion CNS Disord. 2023;25(1):22r03330. - PubMed

LinkOut - more resources